Paratek Pharmaceuticals, Inc. announced the promotion of Evan Loh, M.D., to Chief Executive Officer, effective June 25, 2019. Dr. Loh will continue to serve on the Paratek Board of Directors. Michael Bigham, who has served as Paratek's Chairman and CEO since 2014, will remain active with the company in the newly created role of Executive Chairman.

Dr. Loh has nearly 20 years of experience as a senior executive in the pharmaceutical industry, most recently serving as Paratek's Chief Operating Officer since January 2017 and as President and Chief Medical Officer and a member of the Board of Directors since June 2014. Prior to Paratek's merger with Transcept Pharmaceuticals, Dr. Loh was Chief Medical Officer and Chairman of the Board of Directors of Paratek from June 2012 to June 2014. Prior to joining Paratek, Dr. Loh held multiple senior leadership roles at Pfizer and Wyeth, where he led the successful global registration programs for Torisel and Tygacil.

Dr. Loh currently serves on the Board of Directors of Eiger Biopharmaceuticals, Inc. and as Chairman of the Antimicrobials Working Group. In connection with the appointment of Dr. Loh as Chief Executive Officer, Michael Bigham will remain with Paratek and assume the role of Executive Chairman where he will continue to provide strategic guidance and leadership for the organization. Adam Woodrow has been promoted to President and will retain his current Chief Commercial Officer title.

He will continue to lead the commercial organization to advance the U.S. launch of NUZYRA and will assume responsibility for the company's business development initiatives. Mr. Woodrow joined Paratek in 2014 and has been instrumental in building Paratek's commercial organization and in executing the launch of NUZYRA. Prior to Paratek, Mr. Woodrow launched or led the global strategic marketing and commercial teams for a variety of products including Tygacil, ciprofloxacin, Zosyn, Xeljanz, Enbrel, Zyvox, ReFacto, Benefix and Vyndaqel.

In addition, Randy Brenner has been promoted to Chief Development & Regulatory Officer. Randy joined Paratek in 2015 as a member of the Executive Team, leading the regulatory, quality and manufacturing activities for NUZYRA's development and approval. Mr. Brenner's role will now be expanded to include the development and medical functions for Paratek.

Prior to joining Paratek, Mr. Brenner was Global Head of Regulatory at Shire and held multiple senior regulatory leadership roles for Pfizer and Wyeth, where he was responsible for more than 20 new product approvals globally.